Asked by: Lord Scriven (Liberal Democrat - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what plans they have to move the LeDeR programme onto a statutory footing to mandate the implementation of its findings following the data failures and publication delays associated with the 2023 LeDeR report.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
There are no plans to move the Learning from lives and deaths – people with a learning disability and autistic people (LeDeR) programme onto a statutory footing. NHS England’s national LeDeR policy sets out a clear governance framework and expectation that integrated care boards (ICBs) should prioritise LeDeR reviews within their delivery plans and ensure that actions are implemented to improve services and reduce premature mortality for their local populations. Each ICB is also expected to have an Executive Lead for LeDeR and to produce an annual report about their local LeDeR findings, and to have an Executive Lead on learning disability and autism.
There are strong expectations and accountability mechanisms in place, which aligns with the ambition of the 10-Year Health Plan to distribute power to local systems and drive more holistic, ongoing support in the community. ICBs are held accountable to reduce health inequalities for people with a learning disability through existing national and local governance processes such as the NHS Operating Framework, annual assessments of delivery, and core performance indicators, including on LeDeR, to support improvement activities across all ICBs.
Asked by: Baroness Maclean of Redditch (Conservative - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what estimate they have made of the number of working days lost due poor mental health in each of the last five years.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
The following table shows the number of working days lost due to mental health conditions in the last five years:
Year | Number of days lost due to mental health conditions (millions) | Proportion of days lost due to mental health conditions |
2020 | 20.5 | 13.7% |
2021 | 14.8 | 9.0% |
2022 | 19.0 | 10.1% |
2023 | 18.8 | 12.4% |
2024 | 16.4 | 13.5% |
Source: Office for National Statistics.
The working day is defined as seven hours and 30 minutes.
These estimates were produced using the Labour Force Survey, which is a household survey representative of the United Kingdom labour market, and it is used to produce estimates of employment, unemployment, and economic inactivity in the UK along with many other labour market statistics. Caution should be taken when analysing total days lost for 2020 and 2021, because of the impact of furlough and other policies during the COVID-19 pandemic.
Asked by: Lord Scriven (Liberal Democrat - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what steps NHS England has taken to audit the "automated data process" introduced in Spring 2023; and how it has validated the permanent rectification of the technical defects in mortality data which necessitated the withdrawal of the September 2025 LeDeR report.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
The errors in the updated 2023 Learning from lives and deaths – people with a learning disability and autistic people report, which was produced by King’s College London, were found to be caused by an automated data-processing issue. This meant that some data on the causes of death was missing at the time of analysis. This affected the conclusions originally published. NHS England worked closely with King’s College London, to review the report, and a revised version has now been published on 27 January 2026.
NHS England has also worked with its data processor to correct the automated processing error so that it cannot recur. King’s College London has strengthened its data checking protocols to prevent similar issues in the future. The Department is assured that this issue has now been resolved and these improvements have been applied to the revised report.
Asked by: Baroness Maclean of Redditch (Conservative - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what assessment they have made of (1) public understanding of clinical mental health terminology, and (2) whether misunderstandings in language contribute to increased demand for clinical services.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department has made no assessment of public understanding of clinical mental health terminology, nor whether misunderstandings in language contribute to increased demand for clinical services.
The independent review into mental health conditions, attention deficit hyperactivity disorder and autism will look to understand and provide clarity on the similarities and differences between mental health conditions. It will examine the quality of evidence on what is driving demand, to determine which trends reflect real increase in disorder, which reflect changes in awareness or access, and which are artefacts of measurement or definition. The review will produce a short report setting out conclusions and recommendations for responding to rising need, both within government and across the health system and wider public services.
Asked by: Danny Beales (Labour - Uxbridge and South Ruislip)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to expand the use of optometry-led diagnostic and treatment pathways.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
Integrated care boards are responsible for assessing the health needs of their local population and commissioning primary and secondary eye care services to meet them.
This can already include the commissioning of enhanced eye care services from high street optical practices, including minor and urgent eye care services and glaucoma referral refinement services.
NHS England accelerator pilots have demonstrated that improved IT connectivity and a single point of access can significantly speed up eye care referrals and support more patients to be managed in the community, in line with the ambitions in the 10-Year Health Plan.
Asked by: Danny Beales (Labour - Uxbridge and South Ruislip)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to expand the use of community optometry services.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
Integrated care boards are responsible for assessing the health needs of their local population and commissioning primary and secondary eye care services to meet them.
This can already include the commissioning of enhanced eye care services from high street optical practices, including minor and urgent eye care services and glaucoma referral refinement services.
NHS England accelerator pilots have demonstrated that improved IT connectivity and a single point of access can significantly speed up eye care referrals and support more patients to be managed in the community, in line with the ambitions in the 10-Year Health Plan.
Asked by: Helen Maguire (Liberal Democrat - Epsom and Ewell)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to expand the use of community optometry services.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
Integrated care boards are responsible for assessing the health needs of their local population and commissioning primary and secondary eye care services to meet them.
This can already include the commissioning of enhanced eye care services from high street optical practices, including minor and urgent eye care services and glaucoma referral refinement services.
NHS England accelerator pilots have demonstrated that improved IT connectivity and a single point of access can significantly speed up eye care referrals and support more patients to be managed in the community, in line with the ambitions in the 10-Year Health Plan.
Asked by: Lord Hunt of Kings Heath (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government, in the light of reports about the pricing structure of weight-loss medications used in the NHS, (1) what discussions they have had with Novo Nordisk and Eli Lilly, and (2) what steps they are taking to ensure that costs do not exacerbate regional inequalities in access to treatment.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
Commercial access agreements, including confidential discounts, are negotiated to secure affordability and value for money for the National Health Service, and to enable access to clinically effective treatments that may not otherwise meet cost effectiveness thresholds at list price. As is standard across NHS medicines commissioning, the specific terms of commercial agreements remain confidential to protect the NHS’s negotiating position and to ensure best value for public funds.
NHS England, alongside the Department and the National Institute for Health and Care Excellence, routinely engages with pharmaceutical companies, including Novo Nordisk and Eli Lilly, through standard market access and appraisal processes, and commercial and supply discussions following NICE recommendations, and ongoing dialogue on implementation, demand management, and system readiness. NHS England does not comment publicly on the detail of individual commercial negotiations.
For weight management medicines, NHS England is supporting implementation via a phased and prioritised rollout approach. Prioritising populations with the greatest clinical need aligns with NHS objectives to reduce health inequalities.
NHS England is working with regions and integrated care boards to support consistent implementation of national policy, and to address unwarranted variation through guidance, oversight, and data monitoring. These approaches are designed to ensure that cost pressures do not drive postcode-based inequities, while enabling the safe and sustainable introduction of new treatments at scale.
Asked by: Lord Hunt of Kings Heath (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what steps they plan to take to increase transparency around commercial pricing agreements for new weight-loss medications within the NHS, including how pricing decisions reflect anticipated long-term clinical and economic outcomes.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
Commercial access agreements, including confidential discounts, are negotiated to secure affordability and value for money for the National Health Service, and to enable access to clinically effective treatments that may not otherwise meet cost effectiveness thresholds at list price. As is standard across NHS medicines commissioning, the specific terms of commercial agreements remain confidential to protect the NHS’s negotiating position and to ensure best value for public funds.
NHS England, alongside the Department and the National Institute for Health and Care Excellence, routinely engages with pharmaceutical companies, including Novo Nordisk and Eli Lilly, through standard market access and appraisal processes, and commercial and supply discussions following NICE recommendations, and ongoing dialogue on implementation, demand management, and system readiness. NHS England does not comment publicly on the detail of individual commercial negotiations.
For weight management medicines, NHS England is supporting implementation via a phased and prioritised rollout approach. Prioritising populations with the greatest clinical need aligns with NHS objectives to reduce health inequalities.
NHS England is working with regions and integrated care boards to support consistent implementation of national policy, and to address unwarranted variation through guidance, oversight, and data monitoring. These approaches are designed to ensure that cost pressures do not drive postcode-based inequities, while enabling the safe and sustainable introduction of new treatments at scale.
Asked by: Lord McCrea of Magherafelt and Cookstown (Democratic Unionist Party - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what steps they intend to take to prevent any increase in the number of women performing dangerous late-term abortions at home.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
Parliament decided in 2022 to amend the Abortion Act 1967 to make home use of medical abortion pills a permanent option in England and Wales where the pregnancy has not exceeded 10 weeks gestation. Before pills are prescribed for an early medical abortion at home, the woman requesting the abortion will have had a consultation with a clinician either in person, by telephone, or by electronic means. If the clinician has any concerns about the gestation of the pregnancy during a telephone or electronic consultation, the woman will be asked to attend a clinic.
In June 2025, the House of Commons voted to add a clause to the Crime and Policing Bill which would decriminalise abortion for a woman acting in relation to her own pregnancy. The bill will now progress through Parliament in the usual way and is currently being debated in the House of Lords. Should abortion be decriminalised for a woman acting in relation to her own pregnancy these offences would still apply to medical professionals and third parties who do not abide by the rules set out in the Abortion Act 1967.